1.

MATTERS OF ADMINISTRATION

1.1

Welcome and apologies

1.2

Minutes and recommendations of the 171st MARC meeting

1.3

Declarations of potential conflicts of interest

2.

MATTERS ARISING FROM THE NZ PHARMACOVIGILANCE CENTRE

2.1

CARM quarterly report

3.

PHARMACOVIGILANCE REPORTS

3.1

Matters referred to the MARC under section 36 of the Medicines Act 1981

3.2

Matters referred to the MARC by Medsafe

3.2.1

Assessment of the potential risk of disabling and persistent musculoskeletal and nervous system adverse reactions from the use of fluoroquinolones

3.2.2

Modified-release paracetamol: risk of overdose

3.2.3

Influvac Tetra – Risk Management Plan

3.2.4

Gabapentin and the risk of respiratory depression without concomitant opioids

3.2.5

Natalizumab (Tysabri) and haematological abnormalities in newborns whose mothers were treated with natalizumab during pregnancy

4.

MEDSAFE PHARMACOVIGILANCE ACTIVITIES

4.1

Report on standing agenda items

4.2

Medsafe pharmacovigilance activities

4.3

Prescriber Update

4.4

Quarterly summary of recent safety communications

5.

OTHER BUSINESS

5.1

Therapeutic products regulation project – Update